Defining the structural and functional roles of mutations in gp120 associated with the emergence of HIV-1 clinical resistance to the CCR5 antagonist vicriviroc

被引：0
|
作者：
Howe, J. A. [1 ]
Murgolo, N. [1 ]
Hou, Y. [1 ]
Ba, L. [1 ]
Buontempo, P. [1 ]
Strizki, J. [1 ]
Ogert, R. [1 ]
机构：
[1] Schering Plough Res Inst, Dept Biol Res Virol, Kenilworth, NJ USA
来源：
ANTIVIRAL THERAPY | 2008年 / 13卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
引用
收藏
页码：A36 / A36
页数：1
相关论文
共 50 条
  • [21] Binding Thermodynamics of the N-Terminal Peptide of the CCR5 Coreceptor to HIV-1 Envelope Glycoprotein gp120
    Brower, Evan T.
    Schon, Arne
    Klein, Jeffrey C.
    Freire, Ernesto
    BIOCHEMISTRY, 2009, 48 (04) : 779 - 785
  • [22] HIV-1 gp120氨基酸位点突变与其抗CCR5辅助受体拮抗剂vicriviroc的关系
    邓钦莹
    中国病理生理杂志, 2009, 25 (12) : 2309 - 2309
  • [23] Mutations in gp41 of HIV-1 envelope gene impact on resistance of CCR5 inhibitors
    Wei, Y.
    Chamberland, A.
    Vaisheva, F.
    Belange-Jasmin, G.
    Milan, O. Asin
    Sylla, M.
    Tremblay, C. L.
    ANTIVIRAL THERAPY, 2009, 14 (04) : A110 - A110
  • [24] Modeling of CCR5 Recognition by HIV-1 gp120: How the Viral Protein Exploits the Conformational Plasticity of the Coreceptor
    Jacquemard, Celien
    Koensgen, Florian
    Colin, Philippe
    Lagane, Bernard
    Kellenberger, Esther
    VIRUSES-BASEL, 2021, 13 (07):
  • [25] Preferential recognition of monomeric CCR5 expressed in cultured cells by the HIV-1 envelope glycoprotein gp120 for the entry of R5 HIV-1
    Nakano, Yusuke
    Monde, Kazuaki
    Terasawa, Hiromi
    Yuan, Yuzhe
    Yusa, Keisuke
    Harada, Shinji
    Maeda, Yosuke
    VIROLOGY, 2014, 452 : 117 - 124
  • [26] SIGNATURE MUTATIONS IN V3 AND BRIDGING SHEET DOMAIN OF HIV-1 GP120 HIV-1 ARE SPECIFICALLY ASSOCIATED WITH DUAL TROPISM AND MODULATE THE INTERACTION WITH CCR5 N-TERMINUS
    Alteri, C.
    Artese, A.
    Zhang, J. M.
    Mercurio, F.
    Costa, G.
    Stazi, F.
    Fabeni, L.
    Bertoli, A.
    Forbici, F.
    Salpini, R.
    Dimonte, S.
    Alcaro, S.
    Ceccherini-Silberstein, F.
    Perno, C. F.
    Svicher, V.
    INFECTION, 2011, 39 : S39 - S39
  • [27] Analysis of the prevalence of CCR5 coreceptor antagonist resistance mutations among HIV-1 variants in Russia
    Vasilyev, A. V.
    Kazennova, E. V.
    Bobkova, M. R.
    VOPROSY VIRUSOLOGII, 2011, 56 (03) : 32 - 37
  • [28] Detection of HIV-1 CXCR4 tropism and resistance in treatment experienced subjects receiving CCR5 antagonist-Vicriviroc
    McNicholas, Paul
    Vilchez, Regis A.
    Greaves, Wayne
    Kumar, Sushma
    Onyebuchi, Chinyere
    Black, Todd
    Strizki, Julie M.
    JOURNAL OF CLINICAL VIROLOGY, 2012, 55 (02) : 134 - 139
  • [29] An aptamer that neutralizes R5 strains of HIV-1 binds to core residues of gp120 in the CCR5 binding site
    Cohen, Carla
    Forzan, Mario
    Sproat, Brian
    Pantophlet, Ralph
    McGowan, Ian
    Burton, Dennis
    James, William
    VIROLOGY, 2008, 381 (01) : 46 - 54
  • [30] A highly conserved arginine in gp120 governs HIV-1 binding to both syndecans and CCR5 via sulfated motifs
    de Parseval, A
    Bobardt, MD
    Chatterji, A
    Chatterji, U
    Elder, JH
    David, G
    Zolla-Pazner, S
    Farzan, M
    Lee, TH
    Gallay, PA
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (47) : 39493 - 39504
12345